Kelly, Kevin <br/><br/>
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2017 
 - 1186-1192 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-1207  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aminopyridines--administration & dosage<br/>B-Lymphocytes--drug effects<br/>Benzamides--administration & dosage<br/>Cyclic Nucleotide Phosphodiesterases, Type 4--drug effects<br/>Cyclopropanes--administration & dosage<br/>Drug-Related Side Effects and Adverse Reactions--pathology<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphodiesterase 4 Inhibitors--administration & dosage<br/>Phosphoinositide-3 Kinase Inhibitors